|
Synonyms: MOXR 0916 | MOXR0916 | pogalizumab (deleted INN) | RG7888 | RO7021608
Compound class:
Antibody
Comment: Vonlerolizumab (MOXR0916) was an investigational humanized anti-human OX40 monoclonal, with reported preclinical efficacy [1]. Genentech terminated their Phase 2 trial NCT03029832 and have discontinued further development.
|
| Bioactivity Comments |
| Engagement of OX40 by MOXR0916 enhances IFN-γ production and proliferation of Teff cells, and suppresses Treg cell function in vitro [1]. |
| Selectivity at catalytic receptors | ||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||
